Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio. "As I begin my tenure as ...

Tumors of the central nervous system (CNS) are the most common pediatric tumor type and the leading cause of cancer-related ...

Laney Amplification has expanded its bass amp range with the Digbeth Foundry Series, and it is promising something for all bassists in a suit of amps that range from the ubiquitous bedroom ...

Laney Amplification has expanded its bass amp range with the Digbeth Foundry Series, and it is promising something for all bassists in a suit of amps that range from the ubiquitous bedroom-friendly ...

Targeting SHP2 has emerged as a promising approach for treating cancers driven by receptor tyrosine kinases. Although allosteric SHP2 inhibitors have shown strong antitumor activity in preclinical ...

Approximately 5%-10% of solid tumors carry mutations in one of the four FGFRs, and aberrant FGFR signaling can be involved in oncogenesis and cancer progression. 4 Oncogenic activation of FGFRs occurs ...

Boundless also tested the candidate in combination with the EGFR inhibitor erlotinib and FGFR inhibitor futibatinib, which Taiho Oncology sells as Lytgobi. However, the combinations were not well ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...